{
    "clinical_study": {
        "@rank": "139728", 
        "arm_group": [
            {
                "arm_group_label": "Creon", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Creon N", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion\n      of fat, sugars and proteins) in Cystic Fibrosis"
        }, 
        "brief_title": "A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon\u00ae on Fat Digestion in Subjects \u2265 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis", 
                "Exocrine Pancreatic Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent given by the subject, or the parents, or a legally acceptable\n             representative. If required by the Institutional Review Board/Ethics Committee\n             (IRB/IEC), assent will be given by the subject\n\n          -  Age \u2265 12 years\n\n          -  Subjects who are able to swallow capsules with each meal and snacks\n\n          -  Diagnosis of CF confirmed by two positive chloride sweat tests or gene analysis\n\n          -  Diagnosis of pancreatic exocrine insufficiency proven by:\n\n               1. CFA < 70% without supplementation\n\n               2. or Human fecal elastase < 50 \u03bcg/g stool\n\n          -  Currently receiving treatment with a commercially available pancreatic enzyme product\n             and on a continuous dose of this product for more than 3 months\n\n          -  Clinically stable condition without evidence of acute respiratory disease within 1\n             month of enrollment\n\n          -  Stable body weight defined as no more than a 5% decline within 3 months of enrolment\n\n          -  Females of child-bearing potential should agree to continue using a medically\n             acceptable method of birth control throughout the study and for 30 days immediately\n             after the last dose of study drug. Medically acceptable methods of birth control\n             include bilateral tubal ligation or the use of either a contraceptive implant, a\n             contraceptive injection (Depo-Provera\u2122), an intrauterine device, or an oral\n             contraceptive taken within the past 3 months where the subject agrees to continue\n             using during the study or to adopt another birth control method, or a double-barrier\n             method which consists of a combination of any two of the following: diaphragm,\n             cervical cap, condom, or spermicide.\n\n        Exclusion Criteria:\n\n          -  Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic (except\n             underlying disease), hematologic/immunologic, head, ears, eyes, nose, throat,\n             dermatologic/connective tissue, musculoskeletal, metabolic/nutritional (except\n             underlying disease), endocrine (except diabetes mellitus), neurologic/psychiatric,\n             allergy, recent major surgery, or other relevant diseases as revealed by history,\n             physical examination and/or laboratory assessments, which could limit participation\n             in or completion of the study\n\n          -  History of acute abdomen\n\n          -  History of fibrosing colonopathy\n\n          -  History of distal intestinal obstruction syndrome (DIOS) within 6 months prior to\n             enrollment\n\n          -  Solid organ transplant or surgery affecting the large bowel other than appendectomy\n\n          -  Small bowel surgery that significantly affected absorptive capacity (e.g. gastrectomy\n             or pancreatectomy)\n\n          -  Pregnancy or lactation\n\n          -  Any type of malignancy involving the digestive tract in the last 5 years\n\n          -  Celiac disease or Crohn's disease\n\n          -  Known allergy to pancreatin or inactive ingredients (excipients) of pancreatin\n             capsules\n\n          -  Suspected non-compliance or non-cooperation\n\n          -  Intake of experimental drugs within 30 days prior to study start\n\n          -  Mental disability or any other lack of fitness, in the Investigator's opinion, to\n             preclude subject's participation in or ability to complete the study\n\n          -  Diagnosis of human immunodeficiency virus in medical history."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137382", 
            "org_study_id": "PANC3004", 
            "secondary_id": "2013-002819-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Creon", 
                "description": "active comparator", 
                "intervention_name": "Creon (Pancreatin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Creon N", 
                "description": "experimental drug", 
                "intervention_name": "Creon N (Pancreatin)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pancreatin", 
                "Pancrelipase"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in Cystic Fibrosis", 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1122"
                    }, 
                    "name": "Research facility ID ORG-000826"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary", 
                        "zip": "4031"
                    }, 
                    "name": "Research facility ID ORG-000816"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaposv\u00e1r", 
                        "country": "Hungary", 
                        "zip": "7400"
                    }, 
                    "name": "Research facility ID ORG-000827"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "T\u00f6r\u00f6kb\u00e1lint", 
                        "country": "Hungary", 
                        "zip": "2045"
                    }, 
                    "name": "Research facility ID ORG-000825"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barnaul", 
                        "country": "Russian Federation", 
                        "zip": "656019"
                    }, 
                    "name": "Research facility ID ORG-000821"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "117997"
                    }, 
                    "name": "Research facility ID ORG-000818"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "105077"
                    }, 
                    "name": "Research facility ID ORG-000819"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novosibirsk", 
                        "country": "Russian Federation", 
                        "zip": "630091"
                    }, 
                    "name": "Research facility ID ORG-000824"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orenburg", 
                        "country": "Russian Federation", 
                        "zip": "460035"
                    }, 
                    "name": "Research facility ID ORG-000813"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smolensk", 
                        "country": "Russian Federation", 
                        "zip": "214019"
                    }, 
                    "name": "Research facility ID ORG-000817"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194354"
                    }, 
                    "name": "Research facility ID ORG-000823"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tomsk", 
                        "country": "Russian Federation", 
                        "zip": "634050"
                    }, 
                    "name": "Research facility ID ORG-000812"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Voronezh", 
                        "country": "Russian Federation", 
                        "zip": "394000"
                    }, 
                    "name": "Research facility ID ORG-000822"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation", 
                        "zip": "150003"
                    }, 
                    "name": "Research facility ID ORG-000820"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "8035"
                    }, 
                    "name": "Research facility ID ORG-000829"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "Research facility ID ORG-000828"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Research facility ID ORG-000815"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Hungary", 
                "Russian Federation", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon\u00ae on Fat Digestion in Subjects \u2265 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis", 
        "overall_contact": {
            "email": "gregor.eibes@abbott.com", 
            "last_name": "Gregor H Eibes, PhD"
        }, 
        "overall_official": {
            "affiliation": "Abbott", 
            "last_name": "Suntje Sander-Struckmeier, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Hungary: Scientific and Medical Research Council Ethics Committee", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 [fat intake - fat excretion] / fat intake", 
            "measure": "Coefficient of fat absorption (CFA)", 
            "safety_issue": "No", 
            "time_frame": "5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137382"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 [nitrogen intake - nitrogen excretion] / nitrogen intake)", 
                "measure": "Coefficient of nitrogen absorption (CNA).", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "description": "Total amount of fat excreted during the stool collection period in grams.", 
                "measure": "Total fat excretion", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "description": "Stool frequency is the average of the daily number of stools recorded during the treatment period", 
                "measure": "Stool frequency", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "description": "The percentage of days with no flatulence is calculated from the diary during the treatment period: 100*(number of days with no flatulence/number of days recorded in diary).", 
                "measure": "Percentage of days with no flatulence", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "description": "The percentage of days with no abdominal pain is calculated from the diary during the treatment period: 100*(number of days with no abdominal pain/ number of days recorded in diary).", 
                "measure": "Percentage of days with no abdominal pain", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "description": "The percentage of days with formed/normal stools is calculated from the diary during the treatment period: 100*(number of days with formed/normal stools/ number of days recorded in diary).", 
                "measure": "Percentage of days with formed/normal stools", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }
        ], 
        "source": "Abbott", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}